EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Immunogenicity of an Inactivated COVID-19 Vaccine in People Living with HIV in Guangxi, China: A Prospective Cohort Study

Yuting Wu, Xinwei Wang, Yunxuan Huang, Rongfeng Chen, Yuexiang Xu, Wudi Wei, Fengxiang Qin, Zongxiang Yuan, Jinming Su, Xiu Chen, Jie Liu, Liufang Wen und 12 weitere

Viruses · 2024

DOI: 10.3390/v16091481 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Viruses, 2024. Verfasst von Yuting Wu und 23 weiteren Autor:innen. Beteiligte Einrichtung: Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China. Hauptthemen laut MEDLINE: COVID-19, Antibodies, Viral, Vaccines, Inactivated, COVID-19 Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangxi Science and Technology Department, Guangxi Medical University, Guangxi Science and Technology Base and Talent Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The inactivated COVID-19 vaccine has demonstrated high efficacy in the general population through extensive clinical and real-world studies. However, its effectiveness in immunocompromised individuals, particularly those living with HIV (PLWH), remains limited. In this study, 20 PLWH and 15 HIV-seronegative individuals were recruited to evaluate the immunogenicity of an inactivated COVID-19 vaccine in PLWH through a prospective cohort study. The median age of the 20 PLWH and 15 HIV-seronegative individuals was 42 years and 31 years, respectively. Of the PLWH, nine had been on ART for over five years. The median anti-SARS-CoV-2 S-RBD IgG antibody level on d224 was higher than that on d42 (8188.7 ng/mL vs. 3200.9 ng/mL, P < 0.05). Following COVID-19 infection, the antibody level increased to 29,872.5 ng/mL on dre+90, 12.19 times higher than that on d300. Compared with HIV-seronegative individuals, the antibody level in PLWH was lower on d210 (183.3 ng/mL vs. 509.3 ng/mL, P < 0.01), while there was no difference after d224. The symptoms of COVID-19 infection in PLWH were comparable to those in HIV-seronegative individuals. In this study, the inactivated COVID-19 vaccine demonstrated good immunogenicity in PLWH. The protective benefit of booster vaccinations for PLWH cannot be ignored. Implementing a booster vaccination policy for PLWH is an effective approach to providing better protection against the COVID-19 pandemic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Antibodies, ViralVaccines, InactivatedCOVID-19 VaccinesHIV InfectionsSARS-CoV-2Immunogenicity, VaccineHumansAdultMaleFemaleProspective StudiesChinaMiddle AgedImmunoglobulin GYoung Adult

Stichwörter der Autor:innen

PLWHSARS-CoV-2immunogenicityinactivated COVID-19 vaccine

Substanzen

Antibodies, ViralVaccines, InactivatedCOVID-19 VaccinesImmunoglobulin GSARS-CoV-2 inactivated vaccines

Autor:innen und Institutionen

  • Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.
  • Guigang Center for Disease Control and Prevention, Guigang 537100, China.
  • Joint Laboratory for Emerging Infectious Diseases in China (Guangxi)-ASEAN, Life Sciences Institute, Guangxi Medical University, Nanning 530021, China.
  • National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.

ORCID-Profile: Li Ye, Hao Liang, Junjun Jiang

Förderung

  • Guangxi Science and Technology Department
  • Guangxi Medical University
  • Guangxi Science and Technology Base and Talent Project
  • Guangxi Medical University Training Program for Young Leading Talents
  • Innovation Project of Guangxi Graduate Education

Zitieren

APA

Wu, Y., Wang, X., Huang, Y., Chen, R., Xu, Y., Wei, W., Qin, F., Yuan, Z., Su, J., Chen, X., Liu, J., Wen, L., Shi, M., Qin, T., Liao, Y., Lu, B., Tao, X., Wang, C., Chen, S., …, & Jiang, J. (2024). Immunogenicity of an Inactivated COVID-19 Vaccine in People Living with HIV in Guangxi, China: A Prospective Cohort Study. Viruses. https://doi.org/10.3390/v16091481

Vancouver

Wu Y, Wang X, Huang Y, Chen R, Xu Y, Wei W, et al. Immunogenicity of an Inactivated COVID-19 Vaccine in People Living with HIV in Guangxi, China: A Prospective Cohort Study. Viruses. 2024. doi:10.3390/v16091481

BibTeX
@article{Wu2024,
  author = {Wu, Yuting and Wang, Xinwei and Huang, Yunxuan and Chen, Rongfeng and Xu, Yuexiang and Wei, Wudi and Qin, Fengxiang and Yuan, Zongxiang and Su, Jinming and Chen, Xiu and Liu, Jie and Wen, Liufang and Shi, Minjuan and Qin, Tongxue and Liao, Yinlu and Lu, Beibei and Tao, Xing and Wang, Cuixiao and Chen, Shanshan and Li, Jinmiao and Liu, William J and Ye, Li and Liang, Hao and Jiang, Junjun},
  title = {Immunogenicity of an Inactivated COVID-19 Vaccine in People Living with HIV in Guangxi, China: A Prospective Cohort Study},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16091481}
}
Kostenlos starten →